Skip to main content
. 2009 Mar 5;4(3):e4709. doi: 10.1371/journal.pone.0004709

Figure 8. Application of F(ab) rATG and alemtuzumab fragments abolishes apoptosis and targeting of CD16 on CD56+CD16+ NK cells.

Figure 8

NK cells were treated either with 1 µg/ml rATG or alemtuzumab or with 1 µg/ml F(ab) fragments of rATG or alemtuzumab for 1, 2, 3 and 6 hours. Controls remained untreated. Values of CD56+CD16+ NK cells are displayed as means±SD (n = 5); asterisks (*) indicate significant values compared to controls (***p<0.001, left panel). F(ab) fragments of rATG or alemtuzumab did not induce apoptosis and did not target CD16. Annexin V+/PI− CD56+CD3− cells were normalized to untreated cells. Values are displayed as means±SD of five independent experiments. P values are related to the rATG/alemtuzumab treatment: ***p<0.001.